- Home
- IOVA vs CAPL Comparison
IOVA vs CAPL Comparison
Compare IOVA & CAPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- CAPL
- Stock Information
- Founded
- IOVA 2007
- CAPL 1992
- Country
- IOVA United States
- CAPL United States
- Employees
- IOVA N/A
- CAPL 257
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- CAPL Oil Refining/Marketing
- Sector
- IOVA Health Care
- CAPL Energy
- Exchange
- IOVA Nasdaq
- CAPL Nasdaq
- Market Cap
- IOVA 771.4M
- CAPL 788.6M
- IPO Year
- IOVA N/A
- CAPL 2012
- Fundamental
- Price
- IOVA $1.88
- CAPL $20.74
- Analyst Decision
- IOVA Buy
- CAPL
- Analyst Count
- IOVA 10
- CAPL 0
- Target Price
- IOVA $12.22
- CAPL N/A
- AVG Volume (30 Days)
- IOVA 10.4M
- CAPL 26.5K
- Earning Date
- IOVA 08-07-2025
- CAPL 08-06-2025
- Dividend Yield
- IOVA N/A
- CAPL 10.14%
- EPS Growth
- IOVA N/A
- CAPL 30.34
- EPS
- IOVA N/A
- CAPL 0.80
- Revenue
- IOVA $212,679,000.00
- CAPL $3,694,780,000.00
- Revenue This Year
- IOVA $86.62
- CAPL N/A
- Revenue Next Year
- IOVA $69.95
- CAPL N/A
- P/E Ratio
- IOVA N/A
- CAPL $25.99
- Revenue Growth
- IOVA 11070.12
- CAPL N/A
- 52 Week Low
- IOVA $1.64
- CAPL $18.43
- 52 Week High
- IOVA $12.51
- CAPL $25.73
- Technical
- Relative Strength Index (RSI)
- IOVA 47.47
- CAPL 36.62
- Support Level
- IOVA $1.68
- CAPL $20.55
- Resistance Level
- IOVA $2.02
- CAPL $21.03
- Average True Range (ATR)
- IOVA 0.11
- CAPL 0.43
- MACD
- IOVA 0.03
- CAPL 0.02
- Stochastic Oscillator
- IOVA 61.42
- CAPL 16.90
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About CAPL CrossAmerica Partners LP Common Units representing limited partner interests
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.